Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the bodyâs own machinery â the T-cell â to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patientâs own T-cells to express our SPEAR TCRs to target and potentially destroy tumors. Source
No articles found.
CoverUS is a privacy-by-design based mHealth platform helping to close financial g...
CoverUS is a privacy-by-design based mHealth pl...
We are committed to advancing the treatment of eye conditions such as keratoconus ...
We are committed to advancing the treatment of ...
Insulet Corporation is an innovative medical device company based in Acton, Massac...
Insulet Corporation is an innovative medical de...
Morphic Therapeutic is leading the development of a new generation of oral integri...
Morphic Therapeutic is leading the development ...
Vanda is developing important new medicines to improve the lives of patients. We u...
Vanda is developing important new medicines to ...
ASLAN Pharmaceuticals is a clinical-stage oncology-focused biotechnology company d...
ASLAN Pharmaceuticals is a clinical-stage oncol...
Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceuti...
Dynavax Technologies Corporation (Nasdaq: DVAX)...
Join the National Investor Network and get the latest information with your interests in mind.